extranet

phibro-banner

header4

Conventional Vaccines 

MVP Laboratories provides the animal industry with conventional biologicals that are fully-licensed and manufactured in our state-of-the-art Omaha, Nebraska production facility.

These products come from herd-specific (autogenous) origins and therefore have the additional value of being from highly infectious disease outbreaks.

These products are provided in response to customer needs to have 'off-the-shelf' products available through practicing veterinarians. Additionally, the products are sold through other biological companies via private-label agreements.

MVP Laboratories currently markets two products under our own label through practicing veterinarians:

Bordetella Bronchiseptica Vaccine (avirulent live culture)

This vaccine offers effective, safe and effective atrophic rhinitis prevention in baby pigs.

  • Single dose protection
  • Contains avirulent live cultures of avirulent Bordetella bronchiseptica which colonize and block the adherence of disease-causing strains
  • Back passage studies indicate no reversion to virulence
  • Conveniently delivered intranasally via 0.5 mL in each nostril
  • Effective in the face of antibiotic therapy or maternal antibodies

Bordetella Bronchiseptica Vaccine is available in 30 mL (30-dose) and 100 mL (100-dose) plastic vials.

Emulsibac® APP (Actinobacillus pleuropneumoniae)

Following extensive research and field trial efforts through herd-specific vaccines, Emulsibac® APP was formulated to provide outstanding protection against the most common and virulent serotypes 1, 5 and 7.

  • For prevention of pneumonia in pigs 4 weeks of age or older by infection with the prevalent serotypes of Actinobacillus pleuropneumoniae

  • Product produced through customized culture media and growth conditions that greatly enhance immunogen production and expression of all important soluble toxins
  • Adjuvanted with Emulsigen® to provide amplification of the immune response without injection site reactions
  • Equally effective via SQ or IM routes of administration
  • Controlled studies demonstrated:
  • Significant reduction in clinical signs
  • Significant reduction in body temperatures
  • Significant increase in weight gains

Emulsibac® APP is available in 50-dose (100 mL) and 125-dose (250 mL) plastic vials.

home video